 Virtual Annual Gala will kick off with a goal of raising $1 million to use for innovative research to rid the world of glaucoma and restore vision.

The Gala is 1 of 3 event that take place during the Glaucoma 360 Annual Meeting. The Glaucoma Research Foundation (GRF) uses the annual gala to celebrate the outstanding individuals who strive to achieve the goal of eliminating 

GRF President Thomas Brunner announced recently that The Catalyst Award, the highest honor bestowed by the GRF, will go to Ramin Valian of Allergan, an AbbVie company, to recognize his ongoing leadership and commitment to the development of innovative treatments to advance 

“We are honored to recognize Ramin for his many contributions to ophthalmology that have led to improved glaucoma treatments and provided outstanding educational resources for people with glaucoma and their families,” Brunner said.

Three additional awards will be presented during the event. These include:

The Visionary Award, which will be presented to Amy Dixon of Glaucoma Eyes International for her outstanding dedication to improving the lives of patients with vision loss education.

The 2021 President’s Award, whick will be presented to the Farrell Family to recognize their dedication to fundraising and glaucoma advocacy efforts.

The 2021 Shaffer Prize for Innovative Glaucoma Research will be bestowed on Pete A. Williams, PhD, for his research project titled “Targeting Neuronal Mitochondria for Neuroprotection in Glaucoma,” which has the goal of providing a better understanding of glaucoma thus leading to new treatments.


Glaucoma 360 is comprised of a series of 3 annual events presented by the GRF to highlight the latest advances in glaucoma research as well as the development of novel therapies.

In addition to the annual Gala, the 25th Annual Glaucoma Symposium is the first event and will be held virtually from 8 a.m. to 1 p.m. PST on Saturday, January 23.

This symposium provides an educational opportunity for practicing ophthalmologists and optometrists.

The 10th Annual New Horizons Forum will kick off on January 30 and run from 7 a.m. to approximately 11:30 p.m. PST. This meeting will bring together leaders in glaucoma research and industry who will present new ideas to improve therapies for glaucoma patients.

Interested parties are invited to view www.glaucoma.org and 

 is the president and CEO of Glaucoma Research Foundation.

is vice president of Glaucoma and Reimbursement US, Allergan.

is USA Paratriathlon National Team Member and president of Glaucoma Eyes International.

 is a researcher from the Karolinska Institutet, Stockholm, Sweden.


Articles

GLAUCOMA 360

Amid pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million. 

Glaucoma Research Foundation announces award recipients at G360 virtual annual gala



During AAO 2020, Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Podcasts

Thomas Samuelson, MD, speaks on the outcomes of a three-year trial analyzing the iStent inject trabecular micro-bypass + phaco versus phaco alone in patients with POAG.

Comparing micro-bypass implant + phaco vs phaco in POAG

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of 

 disease in patients enrolled in four trials. 

Videos

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease. 

Safety, efficacy of KPI-121 0.25% for DED treatment


Robert Ang, MD, director, Refractive Surgery Department, Asian Eye Institute (Philippines), discusses highlights of his AAO 2020 presentation on a study titled, "Visual outcomes of small-aperture IOL implantation in post-laser refractive eyes." 

Robert Ang, MD, discusses highlights of his AAO 2020 presentation on a study analyzing the vIsual outcomes of a small-aperture IOL implantation in patients with a history of post-laser refractive surgery.

Visual outcomes of small-aperture IOL implant in post-laser refractive eyes

Richard Lehrer, MD, director of Glaucoma Services, Ohio Eye Alliance Inc, and assistant clinical professor of Ophthalmology, Northeast Ohio Medical University, speaks on the highlights of the study titled, "Success of SLT after trabecular bypass stenting with cataract surgery," which he presented during the 2020 virtual AAO meeting.

Richard Lehrer, MD, speaks on the highlights of a study analyzing the success of SLT after trabecular bypass stenting / phacoemulsification, presented during AAO 2020. 

Success of SLT after trabecular bypass stenting / phaco

Tanner Ferguson, MD, an ophthalmology resident at the Cleveland Clinic's Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 


Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting. 

Evaluating long-term safety of micro-bypass implant with phaco in PXG

Daniel H. Chang, MD, medical director, Empire Eye and Laser Center in Bakersfield, CA, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the American Academy of Ophthalmology's virtual 2020 meeting. 

Daniel H. Chang, MD, speaks on the highlights of his presentation on "Violet Light-Filtering IOLs: Visual and Non-Visual Benefits," during the virtual AAO 2020 meeting.

Visual and non-visual benefits of violet light-filtering IOLs


John A. Hovanesian, MD, clinical instructor, UCLA Jules Stein Eye Institute, Laguna Hills, CA, discusses the highlights of his presentation titled "The D3 Study: Drug Delivery vs Drops — A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% in Controlling Post-operative Pain and Inflammation in Patients Undergoing Sequential Cataract Surgery," during the virtual 2020 American Academy of Ophthalmology (AAO) meeting. 

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.

Drug delivery vs drops: Controlling postop pain, inflammation in cataract surgery patients

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.


Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting. 


Single administration of intracameral bimatoprost implant: IOP lowering, safety

Ehsan Rahimy, MD, speaks on the highlights of a study he presented at this year's virtual AAO 2020 meeting that aimed to integrate an artificial intelligence screening system for managing diabetic retinopathy referrals in a primary care setting — with limited specialty support.



Read and watch more AAO 2020 coverage here